Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.

Medicine - 6 Dec 2024

Liu Min, Li Qiao, Meng Xiaohong, Cui Yanan, Sun Weirong, Wang Hongmei, Gao Qingjun

Abstract excerpt

Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) through immunotherapy, many patients still exhibit resistance to this approach. This study aims to identify the characteristics of individuals who can benefit from immunotherapy, especially immune checkpoint inhibitors (ICIs), and to investigate optimal strategies for patients who experience resistance to it. Data on gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homeodomain Proteins

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Prognosis

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 39654181
DOI: 10.1097/MD.0000000000040569
PMCID: PMC11630944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.PMID 39654181Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.Semantic proximity Read ↗

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.Semantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.